Additionally, 79 percent of these patients achieved excellent or good hemostasis (stoppage of bleeding) over a 12-hour period following infusion. In this study of patients with Factor Xa inhibitor-associated acute major bleeding, a preliminary analysis of interim data from 67 patients (of whom 47 were evaluated for efficacy) showed that AndexXa rapidly and substantially reversed anti-Factor Xa activity (the anticoagulant mechanism of these drugs) when administered as a bolus, and sustained this reversal when followed by a 120-minute infusion. South San Francisco, CA (GLOBE NEWSWIRE) - Portola Pharmaceuticals Inc.®(Nasdaq:PTLA) today announced interim results from the ongoing Phase 3b/4 ANNEXA™-4 study of AndexXa™ (andexanet alfa), a Factor Xa inhibitor antidote. Webcast with ANNEXA-4 Executive Committee Members Today at 11 a.m.Data Presented in Late-Breaking Science Hot Line Session at European Society of Cardiology 2016 Congress and Published in New England Journal of Medicine.AndexXa Rapidly Reversed Anticoagulant Effect of Factor Xa Inhibitors Excellent or Good Hemostasis Was Achieved in 79 Percent of Patients Over 12 Hours.
0 kommentar(er)
